Integra LifeSciences Holdings Corporation (NASDAQ:IART – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $18.19 and last traded at $17.9450, with a volume of 27101 shares traded. The stock had previously closed at $17.77.
Analysts Set New Price Targets
IART has been the subject of several analyst reports. Wells Fargo & Company boosted their target price on Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. Wall Street Zen upgraded Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Truist Financial lowered their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a research report on Wednesday, April 15th. Finally, Argus reiterated a “hold” rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and an average price target of $14.00.
Check Out Our Latest Report on Integra LifeSciences
Integra LifeSciences Trading Up 0.9%
Integra LifeSciences (NASDAQ:IART – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The business had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. During the same quarter in the prior year, the firm posted $0.41 earnings per share. The firm’s revenue for the quarter was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.44 EPS for the current year.
Institutional Investors Weigh In On Integra LifeSciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA increased its holdings in Integra LifeSciences by 27.4% in the first quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock valued at $9,276,000 after purchasing an additional 211,774 shares during the last quarter. Access Investment Management LLC increased its holdings in shares of Integra LifeSciences by 72.0% in the first quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company’s stock worth $6,034,000 after acquiring an additional 268,085 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after acquiring an additional 589,408 shares in the last quarter. Amundi increased its holdings in shares of Integra LifeSciences by 80.8% in the first quarter. Amundi now owns 19,430 shares of the life sciences company’s stock worth $183,000 after acquiring an additional 8,681 shares in the last quarter. Finally, Maverick Capital Ltd. bought a new stake in shares of Integra LifeSciences in the first quarter worth about $679,000. Institutional investors own 84.78% of the company’s stock.
About Integra LifeSciences
Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.
Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.
Featured Articles
- Five stocks we like better than Integra LifeSciences
- Oil Could Dip, But These 3 Energy Stocks Still Look Built to Win
- What’s Behind the Social Media Controversy Surrounding IonQ?
- 3 Long-Duration Treasury ETFs to Watch if Rates Fall
- 3 Dividend Increases Investors Can Actually Trust
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
